secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001140361-25-005988
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore reports 2024 KIMMTRAK net sales of $310M; appoints William Pao to board
--------------------------------------------------------------------------------

- KIMMTRAK Q4 net sales $84.1M; full year $310.0M (+30% YoY); net loss $51.1M ($1.02 EPS) vs $55.3M in 2023.
- Ended 2024 with $820.4M cash; repaid $50M Pharmakon loan in Nov 2024.
- Advanced PRAME pipeline: Phase 3 PRISM-MEL-301 enrolled first patient; IMC-P115C and IMC-R117C first doses in Phase 1.
- Appointed Dr. William Pao (CEO of Revelio Therapeutics) as non-executive director effective Feb 25, 2025.
- Expects to present initial HIV data (IMC-M113V) in Q1 2025 and HBV data (IMC-I109V) in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/0001140361-25-005988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/ef20044296_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer